KPV side effects: what is known and what is not
Reported in people, reported in animals, and unknown.
KPV’s side effects in people are not known: we found no published human trial of KPV. Mouse and cell studies focused on inflammation measures, not on a safety profile. KPV is not FDA-approved, and REMEVi does not currently offer it. Nobody can call it safe or unsafe for you without a licensed provider’s review.
KPV is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer KPV.
Reported in human studies
None found. A PubMed search on November 2, 2026 turned up no published study that gave KPV to people and reported side effects. Human-cell experiments in the lab exist, but cells in a dish cannot show side effects.
Reported in animal studies
The mouse colitis studies (Dalmasso 2008, Kannengiesser 2008, Xiao 2017) measured inflammation, body weight and tissue findings. They were designed to study inflammation, not to establish a side-effect profile, and they used short courses in small groups of mice. Xiao et al. reported that their KPV nanoparticles did not appear toxic to intestinal cells in that study.
What is unknown
- How often any side effect happens in people, at any dose.
- How much oral KPV the human gut absorbs — the reason the policy asks for bioavailability documentation.
- Effects of long-term or repeated use.
- Interactions with other medicines.
- Effects during pregnancy or breastfeeding.
Topical and oral effects
No KPV-specific data describe skin reactions to topical KPV or stomach effects of oral KPV in people. As with any product applied to skin or swallowed, irritation or an allergic reaction is possible. Stop and contact your provider if a rash, swelling or trouble breathing appears.
Who should not use KPV without a provider’s review
- People who are pregnant, trying to conceive or breastfeeding.
- Anyone under 18.
- People with active cancer or a history of cancer — tell your provider.
- Anyone with a known allergy to KPV or to an ingredient in the product.
- Anyone taking other medicines or supplements — share the full list with your provider.
Product quality is a side-effect question too
“Research use only” KPV is outside the HHS policy: no named patient, no requirement for a registered source or certificate of analysis, and no oral bioavailability check. FDA sent warning letters to five online peptide vendors on August 24, 2026.
How to report a side effect
Under the policy, serious adverse events from compounded KPV are reported to FDA MedWatch. You or your provider can file a report directly.
Is KPV safe to use?
There is not enough evidence to answer that. KPV has not been tested in published human trials, so its side effects and risks in people are unknown. It is not FDA-approved. A licensed provider can weigh your health history and medicines, and any serious reaction should be reported to FDA MedWatch.
Sources
- Dalmasso et al., Gastroenterology 2008 — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (read November 2, 2026)
- Kannengiesser et al., Inflammatory Bowel Diseases 2008 — Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease (read November 2, 2026)
- Xiao et al., Molecular Therapy 2017 — Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (read November 2, 2026)
- Elliott et al., Journal of Investigative Dermatology 2004 — Alpha-melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells (read November 2, 2026)
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
- Holland & Knight, Oct 16, 2026 — Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions (read November 2, 2026)
- FDA — MedWatch: The FDA Safety Information and Adverse Event Reporting Program (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·